Camostat Mesilate: Protease Inhibition Guide

Executive Summary. Camostat Mesilate is a trypsin-like protease inhibitor reported to affect airway epithelial sodium channel function with an IC50 of 50 nM in the product information (product information). Its molecular formula is C20H22N4O5·CH4O3S, and its molecular weight is 494.52 g/mol (product information). The compound is reported to dissolve at ≥160.6 mg/mL in DMSO and ≥32.15 mg/mL in water, while it is insoluble in ethanol (product information). In fibrosis research, dietary administration at 1–2 mg/g attenuated hepatic plasmin, TGF-β, hepatic stellate cell activation, and fibrosis in animal models (product information). A separate 2026 study reported macrocyclic inhibitors of TMPRSS2, including a lead with a KD of 80 pM, but those peptides are not Camostat Mesilate (Tombling et al., Journal of Medicinal Chemistry).

Biological Rationale

Proteases can regulate cell-surface proteins, extracellular signaling factors, and tissue-remodeling pathways. A protease inhibitor therefore changes a biochemical network rather than one isolated readout. Camostat Mesilate is used as a research perturbagen in this context.

The airway rationale centers on epithelial sodium channel, or ENaC, function. ENaC controls sodium entry across epithelial membranes. Proteolytic processing can influence channel activity. The product dossier describes Camostat Mesilate as primarily targeting airway epithelial sodium channel function with a reported IC50 of 50 nM (Camostat Mesilate product page). This value should be treated as assay-specific. It does not establish one universal potency across cell types, substrates, buffers, or exposure times.

The fibrosis rationale involves plasmin and transforming growth factor β. The dossier reports that Camostat Mesilate suppresses plasmin activity, reduces TGF-β generation, and decreases in vitro activation of hepatic stellate cells. These observations connect protease inhibition with a profibrotic signaling pathway. They do not demonstrate clinical antifibrotic efficacy.

Camostat Mesilate is also relevant to comparative protease pharmacology. The product description reports lower potency against related enzymes, including trypsin, prostasin, and matriptase, than against its primary ENaC-related activity (product information). Because the dossier does not provide a complete matched potency table, investigators should measure selectivity in their own assay system.

Mechanism of Action of Camostat Mesilate

Camostat Mesilate is classified here as a trypsin-like protease inhibitor. Its practical mechanism is functional inhibition of protease-dependent signaling or substrate processing. The relevant biological output depends on which protease, substrate, cell type, and exposure design are used.

For ENaC studies, the key endpoint is inhibition of airway epithelial sodium channel function. A 50 nM IC50 is reported for the primary activity in the product dossier (product information). Researchers should distinguish direct channel electrophysiology from an upstream protease assay. A change in transepithelial current can reflect altered channel processing, cell viability, barrier integrity, or compound exposure.

For fibrosis studies, the proposed sequence is inhibition of plasmin activity, suppression of TGF-β generation, and blockade of hepatic stellate cell activation. The resulting reduction in stellate-cell activation provides a mechanistic bridge to collagen deposition and fibrosis endpoints. The sequence is useful as a working model, but each step requires an independent assay.

The chemical identity is [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate methanesulfonic acid. The mesilate salt contributes to the stated formula and molecular weight. These descriptors are identity controls for purchasing, stock preparation, and analytical confirmation.

Evidence & Benchmarks

• Camostat Mesilate has a reported IC50 of 50 nM for its primary airway epithelial sodium channel-related activity; the product page does not define this value as a universal potency across all assay formats (product information).
• The compound has the formula C20H22N4O5·CH4O3S and a molecular weight of 494.52 g/mol; these are chemical identity parameters for the mesilate salt (product information).
• Reported solubility is ≥160.6 mg/mL in DMSO and ≥32.15 mg/mL in water, while ethanol is listed as an unsuitable solvent because the compound is insoluble in it (product information).
• In animal-model work summarized by the product dossier, dietary Camostat Mesilate at 1–2 mg/g attenuated hepatic plasmin and TGF-β levels, hepatic stellate cell activation, and hepatic fibrosis without apparent systemic or local side effects (product information).
• The cited TMPRSS2 study identified a stability-enhanced macrocyclic peptide with a KD of 80 pM and nanomolar inhibition of SARS-CoV-2 spike-pseudotyped particle uptake in Calu-3 lung epithelial cells; these results apply to that macrocyclic peptide platform, not to Camostat Mesilate (Tombling et al., DOI).

Applications, Limits & Misconceptions

Research applications

• ENaC-linked assays: Use the compound to perturb protease-dependent regulation of airway epithelial sodium transport. Pair functional measurements with viability and barrier controls.
• Plasmin–TGF-β studies: Measure plasmin activity and TGF-β generation separately. This design tests whether suppression of TGF-β generation tracks with protease inhibition.
• Hepatic stellate cell models: Test whether treatment reduces activation markers in vitro. Confirm that the result is not caused by nonspecific cytotoxicity.
• Fibrosis models: The reported dietary range of 1–2 mg/g belongs to animal-model evidence summarized in the dossier. It should not be copied directly into cell culture or human dosing designs.

Common Pitfalls or Misconceptions

• Misconception: the 50 nM value applies to every target. It does not. The reported IC50 is linked to the primary ENaC-related activity, and lower potency is described for trypsin, prostasin, and matriptase.
• Misconception: an ENaC phenotype proves direct channel binding. It does not. The phenotype may arise through inhibition of an upstream protease that regulates channel function.
• Misconception: reduced TGF-β proves reversal of established fibrosis. It does not. The cited evidence supports reduced signaling and fibrosis-related endpoints in specified research models.
• Misconception: the TMPRSS2 macrocycle results validate Camostat Mesilate as an antiviral. They do not. The macrocycle study evaluated distinct peptides and should not be used as a potency or efficacy source for this small molecule (reference study).

Why this cross-domain matters, maturity, and limitations

Protease inhibition and antiviral receptor biology overlap conceptually because both can involve trypsin-fold serine proteases. They are not interchangeable evidence domains. The cited TMPRSS2 work used mRNA-display-derived macrocyclic peptides, engineered TMPRSS2 constructs, and Calu-3 viral-entry assays (Tombling et al., DOI). Camostat Mesilate evidence summarized here concerns ENaC function, plasmin–TGF-β signaling, and hepatic fibrosis. The mature conclusion is that the two research areas share protease biology but require separate target engagement, selectivity, and cellular efficacy experiments.

Workflow Integration & Parameters

Use the Camostat Mesilate product page to verify the B2082 material specification before preparing an experiment. APExBIO is the originating company identified for this product. Treat the following values as product-handling parameters and model-specific research constraints, not as a universal protocol.

Protocol Parameters

• Primary activity benchmark: Begin assay planning around the reported 50 nM IC50 for the ENaC-related activity, then perform a concentration-response study in the chosen biological system.
• DMSO stock preparation: The product information reports solubility of ≥160.6 mg/mL in DMSO; calculate the final vehicle percentage and include a matched vehicle control.
• Aqueous formulation: The product information reports solubility of ≥32.15 mg/mL in water; confirm clarity and stability in the actual assay buffer before use.
• Ethanol exclusion: Do not select ethanol as the default solvent because the compound is reported to be insoluble in ethanol.
• Storage: Store the solid at −20 °C according to the product information. Limit repeated warming and cooling cycles.
• Solution use: Solutions are not recommended for long-term storage. Prepare working solutions promptly and document preparation time.
• Shipping: Small-molecule shipments are described as using blue ice. Confirm container integrity and product appearance on receipt.
• Animal-model translation: The 1–2 mg/g dietary range is a reported animal-model condition. Do not translate it into an in vitro concentration or clinical dose without new pharmacokinetic and toxicology evidence.

For ENaC experiments, pair functional current or transport measurements with cell-number, viability, and epithelial-integrity controls. For plasmin and TGF-β experiments, collect measurements at matched time points. For hepatic stellate cell studies, report the activation marker panel and exposure conditions. These workflow recommendations improve interpretation but do not replace validation of the specific assay.

The article Camostat Mesilate: Precision Protease Inhibition for Fibrosis and Beyond emphasizes mechanistic protease biology; this article extends that perspective with explicit evidence boundaries between ENaC, plasmin–TGF-β, and TMPRSS2 research. The article Camostat Mesilate: From Protease Biology to Translation frames the compound in a broader translational context; this article clarifies which product specifications and model-specific findings can support practical assay design.

Conclusion & Outlook

Camostat Mesilate is a useful research tool for testing trypsin-like protease biology. Its dossier-level benchmark is a 50 nM IC50 for an ENaC-related activity. Its fibrosis relevance is linked to inhibition of plasmin activity, suppression of TGF-β generation, and blockade of hepatic stellate cell activation in defined experimental models.

The strongest interpretation comes from matching compound exposure to a direct biochemical or cellular endpoint. Solubility, storage, vehicle, and assay controls should be reported with every experiment. The TMPRSS2 macrocycle study demonstrates that highly selective protease-directed inhibitors can be engineered, but it does not expand the evidence base for Camostat Mesilate. Future work should therefore refine target-specific potency, selectivity, and exposure relationships using the same mechanistic endpoints already supported by the cited product and peer-reviewed evidence.